{
    "clinical_study": {
        "@rank": "80681", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "IV Lacosamide administered (intravenously) over 30 minutes:  0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of IV Lacosamide in children ages 4-35."
        }, 
        "brief_title": "IV Lacosamide: The Safety of Intravenous Lacosamide", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "The objective of this study is to evaluate the safety of IV Lacosamide in children ages 4\n      years to 35 years, inclusive who are unable to take oral medications or require parenteral\n      administration of IV Lacosamide  Occasionally, patients over the age of 20 are seen at\n      LeBonheur Children's Hospital due to the complexity of their condition, or due to a long\n      relationship with their physician.  These are exceptions which are reviewed on a case by\n      case basis and are approved by the hospital administrator for admissions and outpatient\n      testing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient or LAR must sign informed consent\n\n          -  Diagnosis of partial onset currently uncontrolled\n\n          -  Patient must have received anti-epileptic drug therapy prior to initiation\n\n          -  Patient must have a medical condition in which parental administration is desireable\n\n          -  Male or female\n\n          -  Ages 4-35\n\n        Exclusion Criteria:\n\n          -  Patient has participated in a study involving IV Lacosamide\n\n          -  Patient has had an episode of status epilepticus in the last 3 months\n\n          -  Drug history to lacosamide pregnant or lactating\n\n          -  If of child bearing age, must have pregnancy test\n\n          -  Patient has participated in an experimental drug study in last 30 days\n\n          -  Patients with significant active hepatic or renal disease.\n\n          -  Patients with known cardiac disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981447", 
            "org_study_id": "09-00570-FB"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "description": "Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.", 
            "intervention_name": "IV Lacosamide", 
            "intervention_type": "Drug", 
            "other_name": "Vimpat"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "epilepsy", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Memphis", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "38103"
                }, 
                "name": "Lebonheur Children's Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "IV Lacosamide: The Safety of Intravenous Lacosamide", 
        "overall_official": {
            "affiliation": "Lebonheur Children's Medical Center", 
            "last_name": "James W Wheless, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The safety of IV Lacosamide will be assessed in patients in whom parental administration of Lacosamide is warranted.", 
            "measure": "To evaluate the safety of IV Lacosamide given as a rapid infusion.", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981447"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Le Bonheur Children's Hospital", 
            "investigator_full_name": "James W. Wheless", 
            "investigator_title": "Principal Investigaor, Neurolgy Division Chief", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Le Bonheur Children's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Le Bonheur Children's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}